{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:54:02Z","timestamp":1789080842667,"version":"build-2803163510"},"reference-count":34,"publisher":"Japan Neurosurgical Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2176\/jns-nmc.2025-0254","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:09:53Z","timestamp":1767910193000},"page":"116-126","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of Clinical Diagnosis-based Treatment in Glioblastoma Patients Aged \u226580 Years: A Single-center Cohort Study Focused on Performance Status Maintenance"],"prefix":"10.2176","volume":"66","author":[{"given":"Takahiro","family":"ONO","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Akita University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"SAITO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Akita University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"ABE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Akita University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"NANJO","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Akita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"SHIMIZU","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Akita University Graduate School of Medicine"},{"name":"Akita Prefectural Hospital Organization and Akita Cerebrospinal and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352 (10):987-96. doi: 10.1056\/NEJMoa043330","DOI":"10.1056\/NEJMoa043330"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Heiland DH, Haaker G, Watzlawick R, et al. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neurooncol. 2018;140 (2):385-91. doi: 10.1007\/s11060-018-2964-8","DOI":"10.1007\/s11060-018-2964-8"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Niare M, Desrousseaux J, Cavandoli C, et al. Outcome of glioblastoma resection in patients 80 years of age and older. Acta Neurochir (Wien). 2022;164 (2):373-83. doi: 10.1007\/s00701-021-04776-5","DOI":"10.1007\/s00701-021-04776-5"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Perry JR, Laperriere N, O&apos;Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376 (11):1027-37. doi: 10.1056\/NEJMoa1611977","DOI":"10.1056\/NEJMoa1611977"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Voisin MR, Sasikumar S, Zadeh G. Predictors of survival in elderly patients undergoing surgery for glioblastoma. Neurooncol Adv. 2021;3 (1):vdab083. doi: 10.1093\/noajnl\/vdab083","DOI":"10.1093\/noajnl\/vdab083"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Karsy M, Yoon N, Boettcher L, et al. Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neurooncol. 2018;138 (1):123-32. doi: 10.1007\/s11060-018-2777-9","DOI":"10.1007\/s11060-018-2777-9"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10 (2):223-8. doi: 10.1215\/15228517-2007-061","DOI":"10.1215\/15228517-2007-061"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Hatakeyama J, Ono T, Takahashi M, et al. Differentiating between primary central nervous system lymphoma and glioblastoma: the diagnostic value of combining <sup>18<\/sup>F-fluorodeoxyglucose positron emission tomography with arterial spin labeling. Neurol Med Chir (Tokyo). 2021;61 (6):367-75. doi: 10.2176\/nmc.oa.2020-0375","DOI":"10.2176\/nmc.oa.2020-0375"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Karschnia P, Young JS, Dono A, et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol. 2023;25 (5):940-54. doi: 10.1093\/neuonc\/noac193","DOI":"10.1093\/neuonc\/noac193"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39 (4):350-7. doi: 10.1016\/j.ctrv.2012.05.008","DOI":"10.1016\/j.ctrv.2012.05.008"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370 (8):709-22. doi: 10.1056\/NEJMoa1308345","DOI":"10.1056\/NEJMoa1308345"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370 (8):699-708. doi: 10.1056\/NEJMoa1308573","DOI":"10.1056\/NEJMoa1308573"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318 (23):2306-16. doi: 10.1001\/jama.2017.18718","DOI":"10.1001\/jama.2017.18718"},{"key":"14","unstructured":"14) Louis DN. WHO classification of tumours of the central nervous system. 5th ed. Lyon: International Agency for Research on Cancer; 2022. p. 568."},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135 (4):639-42. doi: 10.1007\/s00401-018-1826-y","DOI":"10.1007\/s00401-018-1826-y"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Louis DN, Wesseling P, Paulus W, et al. cIMPACT-NOW update 1: not otherwise specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018;135 (3):481-4. doi: 10.1007\/s00401-018-1808-0","DOI":"10.1007\/s00401-018-1808-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant. 2013;48 (3):452-8. doi: 10.1038\/bmt.2012.244","DOI":"10.1038\/bmt.2012.244"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Liu J, Li C, Wang Y, et al. Prognostic and predictive factors in elderly patients with glioblastoma: a single-center retrospective study. Front Aging Neurosci. 2021;13:777962. doi: 10.3389\/fnagi.2021.777962","DOI":"10.3389\/fnagi.2021.777962"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Babu R, Komisarow JM, Agarwal VJ, et al. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016;124 (4):998-1007. doi: 10.3171\/2015.4.JNS142200","DOI":"10.3171\/2015.4.JNS142200"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Barz M, Gerhardt J, Bette S, et al. Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective study. BMC Neurol. 2021;21 (1):446. doi: 10.1186\/s12883-021-02424-0","DOI":"10.1186\/s12883-021-02424-0"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21) Ferles A, Majewska P, Holden Helland R, et al. Estimating overall survival of glioblastoma patients using clinical variables, tumor size, and location. Neurooncol Adv. 2025;7 (1):vdaf154. doi: 10.1093\/noajnl\/vdaf154","DOI":"10.1093\/noajnl\/vdaf154"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Hirsch CH, Sommers L, Olsen A, et al. The natural history of functional morbidity in hospitalized older patients. J Am Geriatr Soc. 1990;38 (12):1296-303. doi: 10.1111\/j.1532-5415.1990.tb03451.x","DOI":"10.1111\/j.1532-5415.1990.tb03451.x"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Khasraw M, Ameratunga MS, Grant R, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014; (9):CD008218. doi: 10.1002\/14651858.CD008218.pub3","DOI":"10.1002\/14651858.CD008218.pub3"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Kaley T, Nolan C, Carver A, et al. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncol. 2013;2 (5):413-8. doi: 10.2217\/cns.13.40","DOI":"10.2217\/cns.13.40"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Hata N, Yoshimoto K, Hatae R, et al. Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. Onco Targets Ther. 2017;10:429-37. doi: 10.2147\/OTT.S125587","DOI":"10.2147\/OTT.S125587"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307 (5706):58-62. doi: 10.1126\/science.1104819","DOI":"10.1126\/science.1104819"},{"key":"27","unstructured":"27) Chugai Pharmaceutical Co. L. Avastin<sup>\u00ae<\/sup> intravenous infusion 100 mg\/4 mL and 400 mg\/16 mL: Interview Form, 2025 [Internet]. Available from: https:\/\/pins.japic.or.jp\/pdf\/medical_interview\/IF00004046.pdf"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28) Makino K, Hirai T, Nakamura H, et al. Differentiating between primary central nervous system lymphomas and glioblastomas: combined use of perfusion-weighted and diffusion-weighted magnetic resonance imaging. World Neurosurg. 2018;112:e1-6. doi: 10.1016\/j.wneu.2017.10.141","DOI":"10.1016\/j.wneu.2017.10.141"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Yamashita K, Yoshiura T, Hiwatashi A, et al. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and <sup>18<\/sup>F-fluorodeoxyglucose positron emission tomography. Neuroradiology. 2013;55 (2):135-43. doi: 10.1007\/s00234-012-1089-6","DOI":"10.1007\/s00234-012-1089-6"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Wang S, Kim S, Chawla S, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011;32 (3):507-14. doi: 10.3174\/ajnr.A2333","DOI":"10.3174\/ajnr.A2333"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Tsougos I, Svolos P, Kousi E, et al. Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging. 2012;12 (3):423-36. doi: 10.1102\/1470-7330.2012.0038","DOI":"10.1102\/1470-7330.2012.0038"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132 (12):e154941. doi: 10.1172\/JCI154941","DOI":"10.1172\/JCI154941"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Shibamoto Y. Radiation therapy for primary central nervous system lymphoma. Oncol Rev. 2013;7 (1):e4. doi: 10.4081\/oncol.2013.e4","DOI":"10.4081\/oncol.2013.e4"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34) Brain tumor registry of Japan (2005-2008). Neurol Med Chir (Tokyo). 2017;57 (suppl 1):9-102. doi: 10.2176\/nmc.sup.2017-0001","DOI":"10.2176\/nmc.sup.2017-0001"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/66\/3\/66_2025-0254\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:01:34Z","timestamp":1774065694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/66\/3\/66_2025-0254\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2025-0254","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"2025-0254"}}